Related Experiment Video
Updated: Jul 1, 2026

12:57
Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
Published on: January 8, 2015
15.7K
Endogenous Ecotropic Murine Leukemia Virus Promotes Prion Pathogenesis in Senescence-accelerated Mice
Min-Woo Choi1,2, Mohd Najib Mostafa1,3, Mo-Jong Kim1
1Ilsong Institute of Life Science, Hallym University, Seoul 07247, Korea.
Experimental Neurobiology
|April 29, 2026
Summary
Endogenous ecotropic murine leukemia virus (E-MuLV) accelerates prion disease in senescence-accelerated mice. This retrovirus promotes prion protein (PrPSc) accumulation, leading to earlier onset and shorter survival in infected mice.
Area of Science:
- Neuroscience
- Virology
- Gerontology
Background:
- Senescence-accelerated prone mice (SAMP) strains show age-related cognitive decline.
- SAMP strains harbor high levels of endogenous ecotropic murine leukemia virus (E-MuLV), unlike resistant SAMR1 mice.
- Retroviruses, including MuLV, are linked to accelerated prion disease pathogenesis.
Purpose of the Study:
- To investigate the role of endogenous E-MuLV in prion disease progression.
- To compare prion disease progression in E-MuLV-carrying SAMP10 mice versus E-MuLV-low SAMR1 mice.
Main Methods:
- Infection of SAMP10 and SAMR1 mice with the 22L scrapie strain via intracerebral and intraperitoneal routes.
- Assessment of survival times, PrPSc accumulation, and vacuolation.
- Treatment of infected cerebellar slice cultures from SAMP10 mice with zidovudine.
Main Results:
- SAMP10 mice exhibited significantly shorter survival times post-scrapie infection compared to SAMR1 mice.
- Earlier and more pronounced PrPSc accumulation and vacuolation were observed in SAMP10 mice.
- Zidovudine treatment reduced PrPSc accumulation in SAMP10 cerebellar slice cultures.
Conclusions:
- Endogenous E-MuLV contributes to accelerated prion pathogenesis.
- E-MuLV promotes early and elevated PrPSc accumulation, shortening survival.
- Targeting retroviral activity may be a strategy to mitigate prion disease progression.

